NasdaqGS - Nasdaq Real Time Price USD

Ovid Therapeutics Inc. (OVID)

Compare

0.9991

-0.0209

(-2.05%)

At close: December 20 at 4:00:01 PM EST

0.9921

-0.01

(-0.70%)

After hours: December 20 at 4:15:01 PM EST

3 US Penny Stocks With Market Caps Over $20M

As the U.S. stock market experiences a downturn, with the S&P 500 on track to end its three-week winning streak, investors are keenly observing opportunities across various sectors. Penny stocks, though often associated with riskier ventures, continue to capture attention due to their potential for substantial returns when backed by strong financials and growth prospects. This article explores three penny stocks that stand out for their solid balance sheets and potential for growth, offering...

Simply Wall St. 7 days ago

DAIO

PXLW

OVID
-2.05%
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin Findings to be presented on the effects of OV329 on elevating GABA and suppressing seizures as evaluated in the lithium-pilocarpine model of status epilepticus A study of the effect of OV350, a KCC2 direct activator, in rescuing animals from nerve agent-induced benzodiazepine-resistant refractory stat

GlobeNewswire 19 days ago

OVID
-2.05%
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

OVID
-2.05%
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs.A regulatory application for a Phase 1 trial of OV350, the first candidate from Ovid's KCC2 direct activator library, is expected to be filed in Q4 2024.The Company will host a KCC2 Download Day on November 13 to provide updates on Ovid's platform of KCC2 direct activators a

GlobeNewswire last month

OVID
-2.05%
US Penny Stocks To Watch This November 2024

As the U.S. stock market continues to rally post-election, with major indices like the S&P 500 and Nasdaq reaching record highs, investors are exploring various opportunities in different corners of the market. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite their somewhat outdated moniker. These stocks can offer potential for growth at lower price points when backed by strong financials and fundamentals, presenting intriguing...

Simply Wall St. last month

INVZ

INVZW

OVID
-2.05%
Ovid Therapeutics to Host Investor Event

KCC2 Download Day on Wednesday, November 13, 2024NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid’s headquarters in New York’s Hudson Yar

GlobeNewswire last month

OVID
-2.05%
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 2 months ago

OVID
-2.05%
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329’s potency, mechanism of inhibition, short half-life, rapid tissue elimination and prolonged pharmacodynamic effect suggests it delivers a differentiated ocular safety and efficacy profile from vigabatrin A Phase 1 trial evaluating OV329 in healthy volunteers is on-track for comp

GlobeNewswire 2 months ago

OVID
-2.05%
After epilepsy setback, Ovid charges confidently ahead in CNS

A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.

Pharma Voice 2 months ago

OVID
-2.05%
TAK
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid’s leadership team to advance Ovid’s development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy. “

GlobeNewswire 3 months ago

OVID
-2.05%
Ovid Therapeutics to Present at Upcoming September Investor Conferences

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference – Ovid will present on September 10th at 3:30 p.m. ET.Cantor Global Healthcare Conference – Ovid will participate in a fireside chat on Tu

GlobeNewswire 3 months ago

OVID
-2.05%
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

OVID
-2.05%
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 154.55% and 20.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

OVID
-2.05%
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded Scientific Advisory Board under the leadership of Dr. Robert Langer, adding top neurologists and neuroscientists to drive pipeline advancementsReduced workforce by 43%, streamlined operations, and initiated an ongoing prioritization process, which includes suspending the OV329 IV program to enable focused investment in priority clinical programsMaintain

GlobeNewswire 4 months ago

OVID
-2.05%
Lilly opens R&D hub; Ovid and Lexicon lay off staff

Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.

BioPharma Dive 4 months ago

LLY

OVID
-2.05%
LXRX
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -4% and 35.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

OVID
-2.05%
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid’s clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company’s leadership team. Dr.

GlobeNewswire 4 months ago

OVID
-2.05%
Ovid Therapeutics to Present at Upcoming August Investor Conferences

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in August: BTIG Virtual Biotechnology Conference – Ovid will participate in a fireside chat on Tuesday, August 6th at 10:00 a.m. ET. 2024 Wedbush PacGrow Healthcare Conference – Ovid will partic

GlobeNewswire 4 months ago

OVID
-2.05%
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contr

GlobeNewswire 4 months ago

OVID
-2.05%
7 Sorry Biotech Stocks Set to Make Investors Sad

Biotech stocks are not for everyone, let’s make that perfectly clear. It’s challenging to invest in a field in which companies – particularly startups – can go for years without seeing a penny of revenue. While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get into too much trouble. Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and te

InvestorPlace 4 months ago

TNXP

OVID
-2.05%
GANX

Performance Overview

Return	OVID	S&P 500
YTD	-68.97%	+24.34%
1-Year	-71.45%	+24.38%
3-Year	-69.26%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ovid Therapeutics Inc. (OVID)

3 US Penny Stocks With Market Caps Over $20M

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

US Penny Stocks To Watch This November 2024

Ovid Therapeutics to Host Investor Event

Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

After epilepsy setback, Ovid charges confidently ahead in CNS

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Ovid Therapeutics to Present at Upcoming September Investor Conferences

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Lilly opens R&D hub; Ovid and Lexicon lay off staff

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

7 Sorry Biotech Stocks Set to Make Investors Sad

Performance Overview